References
- Schulte PA, Waters M. Using molecular epidemiology in assessing exposure for risk assessment. Ann N Y Acad Sci 1999; 895: 101-111 https://doi.org/10.1111/j.1749-6632.1999.tb08079.x
- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-1847 https://doi.org/10.1161/01.CIR.97.18.1837
- Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976; 38(1): 46-51 https://doi.org/10.1016/0002-9149(76)90061-8
- Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81(24): 1879-1886 https://doi.org/10.1093/jnci/81.24.1879
- Selvachandran SN, Hodder RJ, Ballal MS, Jones P, Cade D. Prediction of colorectal cancer by a patient consultation questionnaire and scoring system: A prospective study. Lancet 2002; 360(9329): 278-283 https://doi.org/10.1016/S0140-6736(02)09549-1
- Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003; 139(12): 959-965 https://doi.org/10.7326/0003-4819-139-12-200312160-00005
- Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99(9): 715-726 https://doi.org/10.1093/jnci/djk153
- Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95(6): 470-478 https://doi.org/10.1093/jnci/95.6.470
- Fears TR, Guerry D 4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, et al. Identifying individuals at high risk of melanoma: A practical predictor of absolute risk. J Clin Oncol 2006; 24(22): 3590-3596 https://doi.org/10.1200/JCO.2005.04.1277
- Optenberg SA, Clark JY, Brawer MK, Thompson IM, Stein CR, Friedrichs P. Development of a decision-making tool to predict risk of prostate cancer: The Cancer of the Prostate Risk Index (CAPRI) test. Urology 1997; 50(5): 665-672 https://doi.org/10.1016/S0090-4295(97)00451-2
- Colditz GA, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, et al. Harvard report on cancer prevention volume 4. Harvard Cancer Risk Index: Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 2000; 11(6): 477-488 https://doi.org/10.1023/A:1008984432272
- Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89(3): 227-238 https://doi.org/10.1093/jnci/89.3.227
- Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: Risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25(11): 1417-1422 https://doi.org/10.1200/JCO.2006.09.2452
- Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 1994; 73(3): 643-651 https://doi.org/10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5
- Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002; 360(9336): 817-824 https://doi.org/10.1016/S0140-6736(02)09962-2
- Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas YM, Lenburg ME, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila Pa) 2008; 1(1): 56-64 https://doi.org/10.1158/1940-6207.CAPR-08-0011
- McCanlies E, Landsittel DP, Yucesoy B, Vallyathan V, Luster ML, Sharp DS. Significance of genetic information in risk assessment and individual classification using silicosis as a case model. Ann Occup Hyg 2002; 46(4): 375-381 https://doi.org/10.1093/annhyg/mef055
- Demchuk E, Yucesoy B, Johnson VJ, Andrew M, Weston A, Germolec DR, et al. A statistical model for assessing genetic susceptibility as a risk factor in multifactorial diseases: Lessons from occupational asthma. Environ Health Perspect 2007; 115(2): 231-234
- National Heart Lung and Blood Institute. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack. Bethesda, MD: National Heart Lung and Blood Institute; 2004 [cited 2009 Oct 10]. Available from: URL:http://hp2010.nhlbihin.net/ATPiii/calcula tor.asp
- National Cancer Institute. Breast cancer risk assessment tool. Bethesda, MD: National Cancer Institute; 2007 [cited 2009 Oct 5]. Available from: URL:http://www.cancer. gov/bcrisktool/
- Johnson KM, Dowe DA, Brink JA. Traditional clinical risk assessment tools do not accurately predict coronary atherosclerotic plaque burden: A CT angiography study. AJR Am J Roentgenol 2009; 192(1): 235-243 https://doi.org/10.2214/AJR.08.1056
- Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003; 41(9): 1475-1479 https://doi.org/10.1016/S0735-1097(03)00187-6
- Nasir K, Michos ED, Blumenthal RS, Raggi P. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. J Am Coll Cardiol 2005; 46(10): 1931-1936 https://doi.org/10.1016/j.jacc.2005.07.052
- Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009. Epub 2009 Sep 11 https://doi.org/10.1097/GIM.0b013e3181b9b04a
- Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100(14): 1037-1041 https://doi.org/10.1093/jnci/djn180
- Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009; 101(13): 959-963 https://doi.org/10.1093/jnci/djp130
- Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. InJ Natl Cancer st 2006; 98(17): 1183-1192 https://doi.org/10.1093/jnci/djj329
- Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E15 pharmacogenomics Definitions and Sample Coding; Availability. notice. Fed Regist 2008; 73(68): 19074-19076
- Meyer UA. Pharmacogenetic: five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5(9): 669-676 https://doi.org/10.1038/nrg1428
- Roses AD. Pharmacogenetics in drug discovery and development: A translational perspective. Nat Rev Drug Discov 2008; 7(10): 807-817 https://doi.org/10.1038/nrd2593
- Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine Smethyltransferase gene locus. J Natl Cancer Inst 1999; 91(23): 2001-2008 https://doi.org/10.1093/jnci/91.23.2001
- Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4): 363-375 https://doi.org/10.1056/NEJMoa0808227
- Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27(16): 2604-2614 https://doi.org/10.1200/JCO.2008.20.6300
- Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486 https://doi.org/10.1038/428486a
- Wu X, Gu J, Spitz MR. Strategies to identify pharmacogenomic biomarkers: Candidate gene, pathway-based, and genome-wide approaches. In: Innocenti F, editor. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. New Jersey: Humana Press; 2009. p. 353-370
- Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8): 753-764 https://doi.org/10.1056/NEJMoa0809329
- Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006; 24(26): 4333-339 https://doi.org/10.1200/JCO.2006.05.8768
- Wu X, GU J. Pharmacogenetics in cancer chemotherapy. In: Rebbeck TR, Ambrosone CB, Shields PG, editors. Molecular Epidemiology: Applications in Cancer and Other Human Diseases. New York: Informa Heathcare; 2008. p.113-128
- Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet 2005; 6(2): 109-118 https://doi.org/10.1038/nrg1522
- Ziegler A, Konig IR, Thompson JR. Biostatistical aspects of genome-wide association studies. Biom J 2008; 50(1): 8-28 https://doi.org/10.1002/bimj.200710398
- Hirschhorn JN. Genomewide association studies: Illuminating biologic pathways. N Engl J Med 2009; 360(17): 1699-1701 https://doi.org/10.1056/NEJMp0808934
- National Human Genome Research Institute. A Catalog of Published Genome-Wide Association Studies. Bethesda, MD: National Human Genome Research Institute; 2009 [cited 2009 Oct 5]. Available from: URL: http://www.genome.gov/26525384
- Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy: A genomewide study. N Engl J Med 2008; 359(8): 789-799 https://doi.org/10.1056/NEJMoa0801936
- Center for Drug Evaluation Research, Center for Biologic Evaluation Research, Center for Devices and Radiological Health. Guidance for Industry Pharmacogenomic Data Submissions. Silver Spring, MD: Food and Drug Administration; 2005 [cited 2009 Oct 5]. Available from: URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf
- Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009; 27(24): 4027-4034 https://doi.org/10.1200/JCO.2009.22.3701
- Sparano JA, Paik S. Development of the 21- gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26(5): 721-728 https://doi.org/10.1200/JCO.2007.15.1068
- Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Silver Spring, MD: Food and Drug Administration; 2009 [cited 2009 Oct 5]. Available from: URL:http://www.fda.gov/Drugs/ScienceResearch/Researc hAreas/Pharmacogenetics/ucm083378.htm
- Ulrich CM, Ambrosone CB. Molecular epidemiology designs for prognosis. In:Rebbeck TR, Ambrosone CB, Shields PG, editors. Molecular Epidemiology: Applications in Cancer and Other Human Diseases. New York: Informa Heathcare; 2008: p. 41-52
Cited by
- Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study vol.10, pp.None, 2009, https://doi.org/10.1186/1475-2840-10-96
- Towards a personalized risk assessment for exposure of humans to toxic substances vol.24, pp.2, 2009, https://doi.org/10.1590/1414-462x201600020135